Advertisement
Australia markets close in 1 hour 51 minutes
  • ALL ORDS

    7,805.90
    -93.00 (-1.18%)
     
  • ASX 200

    7,556.10
    -86.00 (-1.13%)
     
  • AUD/USD

    0.6399
    -0.0026 (-0.41%)
     
  • OIL

    84.92
    +2.19 (+2.65%)
     
  • GOLD

    2,402.70
    +4.70 (+0.20%)
     
  • Bitcoin AUD

    97,421.77
    +745.06 (+0.77%)
     
  • CMC Crypto 200

    1,283.36
    +397.82 (+43.54%)
     
  • AUD/EUR

    0.6011
    -0.0019 (-0.32%)
     
  • AUD/NZD

    1.0874
    -0.0001 (-0.01%)
     
  • NZX 50

    11,746.94
    -89.10 (-0.75%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,184.02
    -201.85 (-1.23%)
     
  • NIKKEI 225

    37,182.35
    -897.35 (-2.36%)
     

How Eli Lilly Is Thinning Out the Competition

Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.